CN105749018A - 一种治疗臌胀症的中药组合物及其制剂 - Google Patents
一种治疗臌胀症的中药组合物及其制剂 Download PDFInfo
- Publication number
- CN105749018A CN105749018A CN201610281986.3A CN201610281986A CN105749018A CN 105749018 A CN105749018 A CN 105749018A CN 201610281986 A CN201610281986 A CN 201610281986A CN 105749018 A CN105749018 A CN 105749018A
- Authority
- CN
- China
- Prior art keywords
- powder
- concentrated
- extractum
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 210000000003 hoof Anatomy 0.000 title abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000005325 percolation Methods 0.000 claims abstract description 20
- 241000209140 Triticum Species 0.000 claims abstract description 15
- 235000021307 Triticum Nutrition 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 238000007796 conventional method Methods 0.000 claims abstract description 7
- 239000006187 pill Substances 0.000 claims description 50
- 206010003445 Ascites Diseases 0.000 claims description 27
- 239000006071 cream Substances 0.000 claims description 21
- 239000012141 concentrate Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 235000013312 flour Nutrition 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 4
- 239000002893 slag Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 239000004615 ingredient Substances 0.000 abstract description 4
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract description 3
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 229910052603 melanterite Inorganic materials 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 abstract 2
- 238000000605 extraction Methods 0.000 abstract 2
- 240000000038 Ziziphus mauritiana Species 0.000 abstract 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010030302 Oliguria Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 235000003891 ferrous sulphate Nutrition 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- -1 sublimed preparation Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 241000701408 Euphorbia kansui Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗臌胀症的中药组合物及其制剂的制备方法,所述的制备方法,步骤如下:1)、皂矾、小麦粉碎成10目以上粉末至极细粉;2)、大枣、木香、甘遂用10?95%的乙醇做溶剂,浸渍24小时以上进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取1?5次,每次0.1?5h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00?1.60的浸膏;3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
Description
技术领域:
本发明涉及一种中药组合物,特别涉及一种治疗臌胀症的中药组合物及其制剂。
背景技术:
臌症,是中医对各种胸腹水、水肿、浮肿等症的统称,以胸腹部臌胀如鼓而命名,以腹部胀大、肤色苍黄、腹部脉络暴露为特征。臌症根据病因病机的不同而分为“气臌、血臌、水臌”,传统医学的臌症泛指一切以水肿为主要临床表现的症候,这些证候是由肝、肺、心、肾受病,气、血、水淤积腹内,不能通过身体排泄功能而排出,以致胸腹部日益胀大,最终形成臌胀。
现有治疗臌症的药物主要有臌症丸其处方为皂矾(醋制)、甘遂、大枣(去核炒)、木香等。现有臌症丸为糖衣水丸,除去糖衣后显褐色;味酸、涩。其鉴别方法如下:取本品1g,除去糖衣,研细,加水10ml,煮沸10分钟,滤过,取滤液1ml,加铁氰化钾试液2~3滴,即生成蓝色沉淀,分离,沉淀在稀盐酸中不溶解,加氢氧化钠试液,呈棕色沉淀。
其功能主治如下:利水消肿,除湿健脾。用于臌症,胸腹胀满,四肢浮肿,大便秘结,小便短赤。
臌症丸中的中药成分作用如下:
大枣:别名红枣、干枣、枣子,为鼠李科椬物枣Ziziphus jujuba Mill.的干燥成熟果实。
皂矾:别名绿矾、青矾。本品为硫酸盐类矿物水绿矾的矿石。主含含水硫酸亚铁(FeSO4·7H2O)采挖后,除去杂石。
甘遂:别名主田、重泽、甘藁、陵藁、甘泽、苦泽、白泽、鬼丑、陵泽。本品为大戟科植物甘遂Euphorbia kansui T.N.Liou ex T.P.Wang的干燥块根。
木香:别名蜜香、青木香、五香、五木香。本品为菊科植物木香Aucklandia lappa Decne.的干燥根。
小麦:别名麸麦、浮麦、浮小麦、空空麦、麦子软粒、麦。为禾本科植物小麦Triticum aestivum L.的干燥成熟果实。
现有技术公开了臌症丸的以下相关信息
臌症丸为《中华人民共和国卫生部药品标准》中药成方制剂第二册收载的药品,是临床常用的中成药,由皂矾(醋制)、甘遂、大枣等五味药组成。具有利水消肿、除湿健脾的功效,主要用于臌症、胸腹胀满、四肢浮肿、大便秘结、小便短赤等症状。臌症丸质量标准收载于《中华人民共和国卫生部药品标准》中药成方制剂第二册。内容如下:
【处方】皂矾(醋制)200g甘遂20g大枣(去核炒)200g木香20g小麦(炒)100g
【制法】以上五味,粉碎成细粉,过筛,混匀;用水泛丸,60℃以下干燥,包糖衣,即得。【性状】本品为糖衣水丸,除去糖衣后显褐色;味酸、涩。【功能与主治】利水消肿,除湿健脾。用于臌症,胸腹胀满,四肢浮肿,大便秘结,小便短赤。【用法与用量】饭前服,一次10粒,一日3次,儿童酌减。【注意】不可与甘草同服,忌食盐及芥麦面。【规格】每10粒重1.3g【贮藏】密封,防潮。
以下中国专利描述了质量控制方法
200810056503.5 | 臌症丸及其制剂的质量标准及检测方法 |
201110222362.1 | 臌症丸及其制剂的质量标准及检测方法 |
本发明人在临床和生产实践中发现,现有技术在疗效,稳定性,原料的节约等方面需要改进,以提高药物的作用,延长储存期,减少药物的使用量,提高药物的适应性,为此本发明人对现有技术进行了改进,从而完成了本发明。
发明内容:
为改进现有技术的缺陷,本发明提供一种臌症丸的新的制备方法,本发明所述臌症丸,其配方如下:
优选的发明所述臌症丸,其配方如下:
以上组成是按重量作为配比的,在生产时可按照相应比例增大或减少,如大规模生产可以以公斤为单位,或以吨为单位,小规模生产也可以以毫克为单位,重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的,对于特殊情况,如重症或轻症,肥胖或瘦小的,可以相应调整组成的量的配比,增加或减少不超过100%,药效不变。
以上组成中的单味中药,尤其是臣药和佐药,也可以被适当的具有相同药性的中药替换,替换后的中药制剂其药物作用不变。
本发明的臌症丸中药制剂组合物,是通过将上述配方组成的中药原料经过工,制成药物活性物质,随后,以该物质为原料,需要时加入药物可接受的载体,按照制剂学的常规技术制成的。
本发明的药物活性物质,其在制剂中所占重量百分比可以是0.1-99.9%,其余为药物可接受的载体。本发明的药物制剂组合物,以单位剂量形式存在,所述单位剂量形式是指制剂的单位,如片剂的每片,胶囊的每粒胶囊,口服液的每瓶,颗粒剂每袋等。
本发明的中药制剂组合物可以是任何可药用的剂型,这些剂型包括:片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂。本发明的制剂,优选的是口服剂型,如:胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂等。
本发明的中药制剂组合物,其口服给药的制剂可含有常用的赋形剂,诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂。
适用的填充剂包括纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物,例如羟基乙酸淀粉钠。适宜的润滑剂包括,例如硬脂酸镁。适宜的药物可接受的湿润剂包括十二烷基硫酸钠。
可通过混合,填充,压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中。
口服液体制剂的形式例如可以是水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂,或者可以是一种在使用前可用水或其它适宜的载体复配的干燥产品。这种液体制剂可含有常规的添加剂,诸如悬浮剂,例如山梨醇、糖浆、甲基纤维素、明胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶或氢化食用脂肪,乳化剂,例如卵磷脂、脱水山梨醇一油酸酯或阿拉伯胶;非水性载体(它们可以包括食用油),例如杏仁油、分馏椰子油、诸如甘油的酯的油性酯、丙二醇或乙醇;防腐剂,例如对羟基苯甲酯或对羟基苯甲酸丙酯或山梨酸,并且如果需要,可含有常规的香味剂或着色剂。
本发明的中药制剂组合物,在制备成药剂时可选择性的加入适合的药物可接受的载体,如常用的辅料成分:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的制剂组合物在使用时根据况确定用法用量,可每日服三次,每次1-20剂,如:1-20袋或粒或片。
本发明进一步提供本发明所述制剂组合物的制备方法,所述方法步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用10-95%的乙醇做溶剂,浸渍24小时以上进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取1-5次,每次0.1-5h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
优选的,所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用30-90%的乙醇做溶剂,浸渍,25小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取,1-3次,每次0.5-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
特别优选的,所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用70-90%的乙醇做溶剂,浸渍30小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取2-3次,每次1-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
本发明的方法和现有技术相比,主要活性成分明显增加,药效明显提高,制剂稳定性明显提高,
以下通过实验数据说明本发明的有益效果:
实验内容:
本发明和现有技术进行对比实验
1、药效对比实验:
本研究旨在用大鼠肝硬化腹水模型对本发明药物进行评价
CCl4制备肝硬化模型,用50%混合油溶液按照动物体重进行给药,每周2次,12-15周可形成肝硬化,制备大鼠肝硬化腹水模型,造模成功后服用药物和生理盐水,并对体重、腹围进行测定。
大鼠模型随机分为三组:给药前测定大鼠的体重、腹围,然后分成以下组别:模型空白对照组大鼠给予正常饮食,本发明组给药剂量为2.0g/kg,现有技术组给药剂量为2.0g/kg,每天给药两次,共7天。7天后给药后测定大鼠的体重、腹围,进行统计学分析,比较治疗效果,其中给药剂量2.0g/kg是按照生药量计算的。(n=10,)
结果表明,本发明组和现有技术组各项参数指标变化量与阴性对照组比较,具有明显的统计学差异,本发明组和现有技术组比较,本发明组在效果上明显优于现有技术组。
2、临床实验数据
选择50名肝炎,肝硬化腹水的患者作为治疗对象,随机均分为2组,对实验组的患者使用本发明的中药组合物进行治疗,对照组的患者使用现有技术臌症丸进行治疗。对本发明的中药组合物的临床治疗观察,采用本发明的药物与现有技术臌症丸的治疗效果表:
组别 | n | 显效 | 有效 | 无效 | 有效率 |
本发明 | 25 | 12 | 11 | 2 | 92% |
现有药物 | 25 | 11 | 11 | 3 | 88% |
疗效标准:
显效:腹水及全身症状缓解或消失,肝功能基本恢复正常。
有效:腹水及其他症状明显好转,实验室检查有改善。
无效:腹水未见减轻,其他症状及肝功能无改善或恶化。
临床试验结果显示:2组总有效率比较,差异有显著性意义,本发明组优于臌症丸组(P<0.05)。
3、药物稳定性实验:
将样品放置在40℃±2℃、相对湿度75%±5%的条件下放置于恒温恒湿箱中,以设定时间取样,对有关成分进行含量测定,试验后的初步稳定性试验结果如下:
本发明样品试验后的初步稳定性试验结果
现有技术样品试验后的初步稳定性试验结果
结果显示本发明稳定性更高。
4、主要成分溶出度实验
测定方法:按中国药典溶出度测定法(浆法),以900ml脱气纯化水为溶出介质,温度37+0.5℃,调节转速100r/min,取样品6份,精密称定置于溶出杯中,分别于10min,20min,30min,40min,50min,60min时取样2ml,同时补加同温介质2ml,离心,测定硫酸亚铁的溶出度。
以下分别取本发明实施例1丸剂和市售丸剂各6丸,在不同时间测其有效成分硫酸亚铁的溶出度,结果见下表。
本发明实施例1方法制得的丸剂不同时间溶出度测定数据
市售丸剂不同时间溶出度测定数据
从以上实验数据可以看出,用本发明实施例1方法制得的丸剂,药物在水中易溶,药物有效成份的溶出度大大提高,从而提高药物的生物利用度。
具体实施方式:
以下通过实施例进一步说明本发明,但不作为对本发明的限制。
实施例1
【处方】
皂矾(醋制)200g
甘遂20g
大枣(去核炒)200g
木香20g
小麦(炒)100g
【制法】
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用90%的乙醇做溶剂,浸渍35小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取2-3次,每次2-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3-1)、粉末与浸膏混合、制丸、干燥、打光,制成浓缩丸(浓缩水丸、浓缩蜜丸、浓缩水蜜丸);
3-2)、粉末与浸膏混合、制粒、干燥,制成胶囊剂或片剂。
3-3)、粉末与浸膏混合,加入适量的矫味剂,制粒、干燥、整粒,制成颗粒剂。
3-4)、粉末与浸膏混合,干燥,制成散剂。
实施例2
【处方】
【制法】
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用60%的乙醇做溶剂,浸渍24小时以上,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取2次,每次3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.30-1.60的浸膏;
3-1)、粉末与浸膏混合、制丸、干燥、打光,制成浓缩丸(浓缩水丸、浓缩蜜丸、浓缩水蜜丸);
3-2)、粉末与浸膏混合、制粒、干燥,制成胶囊剂或片剂。
3-3)、粉末与浸膏混合,加入适量的矫味剂,制粒、干燥、整粒,制成颗粒剂。
3-4)、粉末与浸膏混合,干燥,制成散剂。
实施例3
【处方】
【制法】
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用40%的乙醇做溶剂,浸渍48小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取4次,每次1h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.30的浸膏;
3-1)、粉末与浸膏混合、制丸、干燥、打光,制成浓缩丸(浓缩水丸、浓缩蜜丸、浓缩水蜜丸);
3-2)、粉末与浸膏混合、制粒、干燥,制成胶囊剂或片剂。
3-3)、粉末与浸膏混合,加入适量的矫味剂,制粒、干燥、整粒,制成颗粒剂。
3-4)、粉末与浸膏混合,干燥,制成散剂。
Claims (4)
1.一种臌症丸的制备方法,所述臌症丸,其配方如下:
所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用10-95%的乙醇做溶剂,浸渍24小时以上进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取1-5次,每次0.1-5h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
2.根据权利要求1所述的制备方法,其中所述臌症丸,其配方如下:
所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用30-90%的乙醇做溶剂,浸渍,25小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取,1-3次,每次0.5-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
3.根据权利要求1所述的制备方法,其中所述臌症丸,其配方如下:
所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用70-90%的乙醇做溶剂,浸渍30小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取2-3次,每次1-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3)粉末与浸膏混合、作为药物活性成分,根制剂学常规方法制成药物制剂组合物。
4.根据权利要求1所述的制备方法,其中所述臌症丸,其配方如下:
所述的制备方法,步骤如下:
1)、皂矾、小麦粉碎成10目以上粉末至极细粉;
2)、大枣、木香、甘遂用90%的乙醇做溶剂,浸渍35小时,进行渗漉,收集渗漉液,渗漉液滤过,回收乙醇,浓缩至稀膏;渗漉后药渣加水提取2-3次,每次2-3h,合并药液滤过,浓缩,合并上述稀膏浓缩至相对密度1.00-1.60的浸膏;
3-1)、粉末与浸膏混合、制丸、干燥、打光,制成浓缩丸(浓缩水丸、浓缩蜜丸、浓缩水蜜丸);
3-2)、粉末与浸膏混合、制粒、干燥,制成胶囊剂或片剂。
3-3)、粉末与浸膏混合,加入适量的矫味剂,制粒、干燥、整粒,制成颗粒剂。
3-4)、粉末与浸膏混合,干燥,制成散剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610281986.3A CN105749018A (zh) | 2016-04-28 | 2016-04-28 | 一种治疗臌胀症的中药组合物及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610281986.3A CN105749018A (zh) | 2016-04-28 | 2016-04-28 | 一种治疗臌胀症的中药组合物及其制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105749018A true CN105749018A (zh) | 2016-07-13 |
Family
ID=56322519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610281986.3A Pending CN105749018A (zh) | 2016-04-28 | 2016-04-28 | 一种治疗臌胀症的中药组合物及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105749018A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115814025A (zh) * | 2022-10-24 | 2023-03-21 | 江苏艾宠生物科技有限公司 | 一种治疗猫传染性腹膜炎的中药组合物处方及其制备装置 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440772A (zh) * | 2003-04-08 | 2003-09-10 | 邯郸制药有限公司 | 一种治疗膨胀症的中药组合物及其制备方法和质量控制方法 |
CN101229248A (zh) * | 2008-01-21 | 2008-07-30 | 邯郸制药有限公司 | 臌症丸及其制剂的质量标准及检测方法 |
-
2016
- 2016-04-28 CN CN201610281986.3A patent/CN105749018A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440772A (zh) * | 2003-04-08 | 2003-09-10 | 邯郸制药有限公司 | 一种治疗膨胀症的中药组合物及其制备方法和质量控制方法 |
CN101229248A (zh) * | 2008-01-21 | 2008-07-30 | 邯郸制药有限公司 | 臌症丸及其制剂的质量标准及检测方法 |
Non-Patent Citations (3)
Title |
---|
孙世光等: "《新编医院药学》", 31 March 2010, 北京军事医学科学出版社 * |
贾水莲等: "中药成方制剂治疗肝硬化的品种概况", 《浙江中医药大学学报》 * |
鞠玲卉: "中成药制剂治疗肝硬化的品种分析", 《亚太传统医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115814025A (zh) * | 2022-10-24 | 2023-03-21 | 江苏艾宠生物科技有限公司 | 一种治疗猫传染性腹膜炎的中药组合物处方及其制备装置 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100349597C (zh) | 一种治疗病毒性心肌炎的中药制剂及其制法和质量控制方法 | |
CN102670763A (zh) | 一种对化学性肝损伤具有辅助保护作用的组合物及其制备方法 | |
CN102120015A (zh) | 一种用于舒肝解郁、安神定志的中药及制法和质量标准 | |
CN102697982B (zh) | 一种具有辅助降血脂功能的组合物及其制备方法 | |
CN101816723B (zh) | 中药醒酒护肝药剂及其制备方法 | |
WO2008061447A1 (fr) | Médicament pour traiter l'eczéma et procédés d'application cutanée de ce médicament | |
CN103006838A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN102671178B (zh) | 一种治疗肾病综合症及尿毒症的中药组合物配制方法及应用 | |
CN108837121A (zh) | 一种治疗高尿酸的中药组合物及其制备方法 | |
CN105749018A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105796975A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN1679697A (zh) | 一种含有三七、瓜蒌皮、水蛭的治疗心血管疾病的中药制剂及其制备方法 | |
CN100509009C (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN103110884B (zh) | 一种治疗慢性胆囊炎的中药组合物 | |
CN111419999B (zh) | 治疗高尿酸血症的中药组合物及其制备方法 | |
CN105749015A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105749020A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105796976A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105920389A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105920390A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105749017A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN1128632C (zh) | 治疗慢性乙型肝炎的中药复方制剂及制备方法 | |
CN105770567A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105749019A (zh) | 一种治疗臌胀症的中药组合物及其制剂 | |
CN105770566A (zh) | 一种治疗臌胀症的中药组合物及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160713 |